New targeted drug takes on stomach cancer in Head-to-Head trial
Disease control
Completed
This phase 2 trial compares two oral targeted drugs—ripretinib and sunitinib—in 108 people with advanced gastrointestinal stromal tumors (GIST) whose cancer has worsened on or who cannot tolerate imatinib. The main goal is to see which drug better delays cancer growth. Participan…
Phase: PHASE2 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC